Lupin is currently trading at Rs 1484.40, up by 9.90 points or 0.67% from its previous closing of Rs 1474.50 on the BSE.
The scrip opened at Rs. 1497.65 and has touched a high and low of Rs. 1502.55 and Rs. 1470.00 respectively. So far 231454 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2127.00 on 06-Oct-2015 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1544.50 and Rs. 1294.05 respectively. The current market cap of the company is Rs. 66825.96 crore.
The promoters holding in the company stood at 46.53% while Institutions and Non-Institutions held 43.56% and 9.92% respectively.
Lupin’s US subsidiary -- Lupin Pharmaceuticals has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept Tablets, 23mg. Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type. Aricept had US sales of $47.1 million (IMS MAT December 2015).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
